KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Prelimi...(ce in anticipation of the previously dis...),Health

Research and development expenses of $11.3 million for the third quarter of fiscal 2008 were up $2.9 million, or 35.3% compared to the prior year period and reflected an increase of 44.7% to $32.7 million for the nine-month period.

Financial Highlights:

-- 40.6% increase in year-to-date net revenues

-- 50.2% increase in year-to-date gross profit

-- 96.8% increase in year-to-date net income

-- 89.2% increase in year-to-date diluted earnings per Class A Common

Share

BUSINESS SEGMENT HIGHLIGHTS:

Ther-Rx Corporation

-- 15.2% revenue growth year-to-date

-- Clindesse(R) currently holds 27.9% of total prescription volume in the

intra-vaginal bacterial vaginosis market, more than all other

Clindomycin-based intra-vaginal products combined

-- Gynazole-1(R) remains the #1 branded prescription vaginal yeast product

in the United States

-- Ther-Rx continues to be the leading provider of prescription prenatal

vitamins in the United States with 42.5% of the branded prescription

prenatal market

-- Repliva 21/7(TM) continues to be the fastest growing prescription oral

iron supplement in the United States improving its market share by

47.2% since the end of December 2006

Net revenues for the Ther-Rx branded marketing subsidiary increased 16.6% for the quarter to $56.3 million, compared to $48.3 million for the third quarter of fiscal 2007. Net revenues increased 15.2% for the nine-month period to $159.5 million, compared to $138.5 million in the prior year period. Gross margin for the nine-month period reached 89.6% up from 88.3% for the first nine months of fiscal 2007.

Ther-Rx prescription prenatal vita
'/>"/>